Moneycontrol PRO
HomeNewsMarksans pharma

Marksans Pharma

Jump to
  • Marksans Pharma Standalone June 2025 Net Sales at Rs 319.73 crore, up 25.62% Y-o-Y

  • Stocks to Watch Today: IndusInd Bank, Waaree Energies, NTPC Green, KEC, Torrent Pharma, PNC Infra, RPSG Ventures, Monarch Surveyors in focus on 29 July

    Stocks to Watch Today: IndusInd Bank, Waaree Energies, NTPC Green, KEC, Torrent Pharma, PNC Infra, RPSG Ventures, Monarch Surveyors in focus on 29 July

    Stocks to Watch, 29 July: Stocks like IndusInd Bank, Waaree Energies, NTPC Green Energy, KEC International, Torrent Pharma, PNC Infratech, RPSG Ventures, Monarch Surveyors, Paradeep Phosphates, and Mazagon Dock Shipbuilders will be in focus on July 29.

  • Trade Spotlight: How should you trade Relaxo Footwears, Chennai Petroleum, Transrail Lighting, CCL Products, Marksans Pharma, Titan, and others on July 7?

    Trade Spotlight: How should you trade Relaxo Footwears, Chennai Petroleum, Transrail Lighting, CCL Products, Marksans Pharma, Titan, and others on July 7?

    Consolidation is expected to continue in the upcoming sessions, with resistance and support at last week's high-low. Below are some short-term trading ideas to consider.

  • Stocks to Watch Today: Zydus Lifesciences, CE Info Systems Nazara Tech, Sterlite Technologies, HG Infra, Hindustan Copper, Angel One in focus on 12 June

    Stocks to Watch Today: Zydus Lifesciences, CE Info Systems Nazara Tech, Sterlite Technologies, HG Infra, Hindustan Copper, Angel One in focus on 12 June

    Stocks to watch, 12, June: Stocks like Cyient, ICICI Bank, Maruti Suzuki India, Canara Bank, Kellton Tech Solutions, GMM Pfaudler, Titagarh Rail Systems, Zydus Lifesciences, CE Info Systems Nazara Technologies, Sterlite Technologies, HG Infra Engineering, Hindustan Copper, and Angel One will be in focus on June 12.

  • Marksans Pharma block deal: Shares worth Rs 250 crore change hands, OrbiMed likely seller

    Marksans Pharma block deal: Shares worth Rs 250 crore change hands, OrbiMed likely seller

    rbiMed Asia IV Mauritius FVCI Ltd has launched a Rs 256.8 crore stake sale, representing 2.27 percent of the company’s equity, at Rs 249.95 per share.

  • Marksans Pharma Consolidated March 2025 Net Sales at Rs 708.46 crore, up 26.51% Y-o-Y

    Marksans Pharma Consolidated March 2025 Net Sales at Rs 708.46 crore, up 26.51% Y-o-Y

  • Marksans Pharma Standalone March 2025 Net Sales at Rs 299.36 crore, up 32.93% Y-o-Y

    Marksans Pharma Standalone March 2025 Net Sales at Rs 299.36 crore, up 32.93% Y-o-Y

  • Stocks to Watch Today: Power Grid, Bharat Electronics, DLF, Rail Vikas Nigam, HFCL, Shyam Metalics, ACME Solar, Borosil, Petronet LNG in focus on 20 May

    Stocks to Watch Today: Power Grid, Bharat Electronics, DLF, Rail Vikas Nigam, HFCL, Shyam Metalics, ACME Solar, Borosil, Petronet LNG in focus on 20 May

    Stocks to Watch, 20 May: Stocks like CMS Info Systems, GMR Power and Urban Infra, New India Assurance Company, Marksans Pharma, Ami Organics, Bharat Bijlee, Le Travenues Technology, Mangalam Organics, Integrity Infrabuild Developers, Power Grid Corporation of India, Bharat Electronics, DLF, ACME Solar Holdings, Borosil, Petronet LNG, and DOMS Industries will be in focus on May 20.

  • Marksans Pharma Consolidated December 2024 Net Sales at Rs 681.85 crore, up 16.33% Y-o-Y

    Marksans Pharma Consolidated December 2024 Net Sales at Rs 681.85 crore, up 16.33% Y-o-Y

  • Marksans Pharma Standalone December 2024 Net Sales at Rs 311.87 crore, up 29.21% Y-o-Y

    Marksans Pharma Standalone December 2024 Net Sales at Rs 311.87 crore, up 29.21% Y-o-Y

  • Trade Spotlight: How should you trade Siemens, Torrent Pharma, Data Patterns, CAMS, PB Fintech, LTIMindtree, and others on Wednesday?

    Trade Spotlight: How should you trade Siemens, Torrent Pharma, Data Patterns, CAMS, PB Fintech, LTIMindtree, and others on Wednesday?

    The benchmark indices are expected to consolidate in the upcoming sessions and look for fresh triggers. Below are some trading ideas for the near term.

  • Marksans Pharma Consolidated September 2024 Net Sales at Rs 641.92 crore, up 20.84% Y-o-Y

    Marksans Pharma Consolidated September 2024 Net Sales at Rs 641.92 crore, up 20.84% Y-o-Y

  • Marksans Pharma Standalone September 2024 Net Sales at Rs 308.63 crore, up 50.79% Y-o-Y

    Marksans Pharma Standalone September 2024 Net Sales at Rs 308.63 crore, up 50.79% Y-o-Y

  • Marksans Pharma Consolidated June 2024 Net Sales at Rs 590.62 crore, up 18.12% Y-o-Y

    Marksans Pharma Consolidated June 2024 Net Sales at Rs 590.62 crore, up 18.12% Y-o-Y

  • Marksans Pharma Standalone June 2024 Net Sales at Rs 254.53 crore, up 39.82% Y-o-Y

    Marksans Pharma Standalone June 2024 Net Sales at Rs 254.53 crore, up 39.82% Y-o-Y

  • Marksans Pharma stock skyrockets 13% on strong all-round Q1 earnings show

    Marksans Pharma stock skyrockets 13% on strong all-round Q1 earnings show

    Marksans Pharma delivered double-digit revenue as well as net profit growth in April-June along with an expansion in its operating margins.

  • Marksans Pharma Consolidated March 2024 Net Sales at Rs 560.01 crore, up 15.23% Y-o-Y

    Marksans Pharma Consolidated March 2024 Net Sales at Rs 560.01 crore, up 15.23% Y-o-Y

  • Marksans Pharma Standalone March 2024 Net Sales at Rs 225.20 crore, up 47.14% Y-o-Y

    Marksans Pharma Standalone March 2024 Net Sales at Rs 225.20 crore, up 47.14% Y-o-Y

  • Marksans Pharma gains on UK health regulator nod to market new oral solution

    Marksans Pharma gains on UK health regulator nod to market new oral solution

    Marksans Pharma received the UK health regulator's nod to market its new oral solution for epilepsy patients.

  • What drew MIT's investment arm to this small cap pharma company?

    What drew MIT's investment arm to this small cap pharma company?

    MIT's recent investment in Marksans Pharma underscores the small-cap's hidden gem status, fuelled by its strong presence in stable OTC markets and strategic growth initiatives, signalling promising prospects for revenue and profit expansion.

  • USFDA issues Form 483 with five inspectional observations to Marksans Pharma's Goa unit

    USFDA issues Form 483 with five inspectional observations to Marksans Pharma's Goa unit

    The US Food and Drug Administration (USFDA) had conducted a routine current Good Manufacturing Practices (cGMP) inspection at the manufacturing facility from April 9-17, 2024, the company said in a regulatory filing.

  • Marksans Pharma Consolidated December 2023 Net Sales at Rs 586.13 crore, up 22.15% Y-o-Y

    Marksans Pharma Consolidated December 2023 Net Sales at Rs 586.13 crore, up 22.15% Y-o-Y

  • Marksans Pharma Standalone December 2023 Net Sales at Rs 241.36 crore, up 39.72% Y-o-Y

    Marksans Pharma Standalone December 2023 Net Sales at Rs 241.36 crore, up 39.72% Y-o-Y

  • Marksans Pharma Standalone September 2023 Net Sales at Rs 204.67 crore, up 20.21% Y-o-Y

    Marksans Pharma Standalone September 2023 Net Sales at Rs 204.67 crore, up 20.21% Y-o-Y

  • Marksans Pharma gains on USFDA nod to flu drug

    Marksans Pharma gains on USFDA nod to flu drug

    Gguaifenesin helps loosen phlegm and thin bronchial secretions to rid the bronchial passageways of mucus, the company has said

Advisory Alert: It has come to our attention that certain individuals are representing themselves as affiliates of Moneycontrol and soliciting funds on the false promise of assured returns on their investments. We wish to reiterate that Moneycontrol does not solicit funds from investors and neither does it promise any assured returns. In case you are approached by anyone making such claims, please write to us at grievanceofficer@nw18.com or call on 02268882347